News Releases

ALKINDI ® SPRINKLE is now exclusively available through AnovoRx Specialty Pharmacy . To support patient access to ALKINDI ® SPRINKLE, Eton has established the Eton Cares Program ® . DEER PARK, Ill. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty

DEER PARK, Ill. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results for the third quarter ended September 30,

DEER PARK, Ill. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 financial and

DEER PARK, Ill. , Oct. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000

- Application Assigned a PDUFA Date of May 29, 2021 DEER PARK, Ill. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S.

DEER PARK, Ill. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offering of 2,800,000

DEER PARK, Ill. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stock in an

- Application Assigned a PDUFA Date of May 27, 2021 - Dehydrated Alcohol Injection Market Estimated to be Greater Than $100 Million Annually - Application has Received Orphan Drug Designation for Methanol Poisoning DEER PARK, Ill. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc

- Application Submitted for the Treatment of Partial-Onset Seizures and Migraine - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Topiramate - Topiramate Oral Solution is Eton’s Third Neurology Product Candidate Submitted to the FDA DEER PARK, Ill. , Oct.

-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children -Eton expects ALKINDI SPRINKLE to be available in the fourth quarter of 2020 DEER PARK, Ill. , Sept.